JP2016537012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537012A5 JP2016537012A5 JP2016542333A JP2016542333A JP2016537012A5 JP 2016537012 A5 JP2016537012 A5 JP 2016537012A5 JP 2016542333 A JP2016542333 A JP 2016542333A JP 2016542333 A JP2016542333 A JP 2016542333A JP 2016537012 A5 JP2016537012 A5 JP 2016537012A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- nucleic acid
- seq
- encoded
- calreticulin gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 404
- 108020004707 nucleic acids Proteins 0.000 claims description 379
- 102000039446 nucleic acids Human genes 0.000 claims description 379
- 108090000623 proteins and genes Proteins 0.000 claims description 296
- 102000004169 proteins and genes Human genes 0.000 claims description 277
- 239000002773 nucleotide Substances 0.000 claims description 165
- 125000003729 nucleotide group Chemical group 0.000 claims description 165
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 118
- 108090000549 Calreticulin Proteins 0.000 claims description 96
- 238000000034 method Methods 0.000 claims description 91
- 108700028369 Alleles Proteins 0.000 claims description 68
- 230000000295 complement effect Effects 0.000 claims description 49
- 230000002068 genetic effect Effects 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 239000003112 inhibitor Substances 0.000 claims description 30
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 29
- 230000037433 frameshift Effects 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 102000004082 Calreticulin Human genes 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 7
- 238000003364 immunohistochemistry Methods 0.000 claims description 6
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 206010028537 myelofibrosis Diseases 0.000 claims description 4
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 238000012340 reverse transcriptase PCR Methods 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 208000009527 Refractory anemia Diseases 0.000 claims description 2
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims description 2
- 208000005485 Thrombocytosis Diseases 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims description 2
- 230000009149 molecular binding Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108091060271 Small temporal RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13184632.1 | 2013-09-16 | ||
| EP13184632 | 2013-09-16 | ||
| EP13186939.8 | 2013-10-01 | ||
| EP13186939 | 2013-10-01 | ||
| US201361909313P | 2013-11-26 | 2013-11-26 | |
| US61/909,313 | 2013-11-26 | ||
| PCT/EP2014/069638 WO2015036599A1 (en) | 2013-09-16 | 2014-09-15 | Mutant calreticulin for the diagnosis of myeloid malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020022378A Division JP2020109092A (ja) | 2013-09-16 | 2020-02-13 | 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537012A JP2016537012A (ja) | 2016-12-01 |
| JP2016537012A5 true JP2016537012A5 (https=) | 2017-11-02 |
| JP6745220B2 JP6745220B2 (ja) | 2020-08-26 |
Family
ID=51795161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542333A Active JP6745220B2 (ja) | 2013-09-16 | 2014-09-15 | 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン |
| JP2022177306A Active JP7646221B2 (ja) | 2013-09-16 | 2022-11-04 | 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022177306A Active JP7646221B2 (ja) | 2013-09-16 | 2022-11-04 | 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9371570B2 (https=) |
| EP (5) | EP3494985B1 (https=) |
| JP (2) | JP6745220B2 (https=) |
| KR (1) | KR102433548B1 (https=) |
| CN (3) | CN105916876A (https=) |
| AU (2) | AU2014320262B2 (https=) |
| BR (1) | BR112016005611B1 (https=) |
| CA (1) | CA2924370C (https=) |
| DK (3) | DK2808338T3 (https=) |
| ES (1) | ES2577289T3 (https=) |
| MX (1) | MX348980B (https=) |
| PL (2) | PL3494985T3 (https=) |
| PT (1) | PT2808338E (https=) |
| RU (1) | RU2668808C2 (https=) |
| SG (1) | SG11201601193TA (https=) |
| WO (1) | WO2015036599A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX348980B (es) | 2013-09-16 | 2017-07-05 | Cemm-Forschungszentrum Für Molekulare Medizin Gmbh | Calreticulina mutante para la diagnosis de malignidades mieloides. |
| US10550435B2 (en) | 2014-11-12 | 2020-02-04 | Neogenomics Laboratories, Inc. | Determining tumor load and biallelic mutation in patients with CALR mutation using peripheral blood plasma |
| WO2016087514A1 (en) * | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
| US20180237797A1 (en) * | 2015-03-30 | 2018-08-23 | Jeffrey Thomas Loh | Methods for in vitro production of platelets and compositions and uses thereof |
| MX389138B (es) * | 2015-04-23 | 2025-03-20 | Quest Diagnostics Invest Inc | Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas. |
| KR101953092B1 (ko) | 2015-11-11 | 2019-06-13 | 가톨릭대학교 산학협력단 | Ｂｃｒ／ａｂｌ 음성 골수증식종양 관련 유전자변이 다중검출용 펩티드핵산 프로브, 이를 포함하는 유전자변이 다중검출 조성물, 다중검출 키트 및 유전자변이 다중검출방법 |
| ITUA20162858A1 (it) * | 2016-04-26 | 2017-10-26 | Univ Degli Studi Di Torino | Procedimento per la rivelazione di mutazioni di tipo 1 e 2 del gene calreticulina (calr) e relativo kit |
| EP3468585A2 (en) * | 2016-06-10 | 2019-04-17 | IO Biotech APS | Calr and jak2 vaccine compositions |
| CN106566875A (zh) * | 2016-09-20 | 2017-04-19 | 上海荻硕贝肯医学检验所有限公司 | 用于检测骨髓异常增生综合征mds基因突变的引物、试剂盒及方法 |
| CN107164473B (zh) * | 2017-05-22 | 2020-08-25 | 复旦大学附属华山医院 | 一种检测calr基因1型突变的引物组合物及试剂盒 |
| CN107164474B (zh) * | 2017-05-22 | 2020-09-04 | 复旦大学附属华山医院 | 一种检测calr基因2型突变的引物组合物及试剂盒 |
| CN108949971A (zh) * | 2017-05-23 | 2018-12-07 | 曹国君 | 钙网蛋白基因1型突变检测用封闭pna探针 |
| CN107462706A (zh) * | 2017-08-01 | 2017-12-12 | 广西中医药大学附属瑞康医院（广西中西医结合医院） | 一种肿瘤试剂盒 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| CN108434439B (zh) * | 2018-01-23 | 2020-02-07 | 中国人民解放军总医院 | 钙网蛋白的医药用途 |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| RU2679653C1 (ru) * | 2018-08-01 | 2019-02-12 | Общество с ограниченной ответственностью "Формула гена" | Набор реактивов для выявления Ph-негативных миелопролиферативных новообразований и способ диагностики на его основе |
| WO2020084005A1 (en) | 2018-10-23 | 2020-04-30 | Myelopro Diagnostics And Research Gmbh | Compounds targeting mutant calreticulin |
| EP3927746A1 (en) * | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| SG11202108494YA (en) * | 2019-02-28 | 2021-09-29 | Juntendo Educational Found | Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm |
| CN114302967A (zh) * | 2019-08-30 | 2022-04-08 | 东洋钢钣株式会社 | 用于评价骨髓增殖性肿瘤相关基因突变的试剂盒 |
| IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
| CN112795647B (zh) * | 2019-11-14 | 2022-08-16 | 北京肿瘤医院(北京大学肿瘤医院) | 一种肿瘤标志物及其应用 |
| CR20220220A (es) * | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| EP4121081A4 (en) * | 2020-03-17 | 2024-04-17 | Memorial Sloan Kettering Cancer Center | VACCINES AGAINST HETEROCLITIC CANCER |
| CN116322763A (zh) * | 2020-08-27 | 2023-06-23 | 学校法人顺天堂 | 抗切断型突变calr-cd3双特异性抗体及医药组合物 |
| TW202342097A (zh) | 2022-02-25 | 2023-11-01 | 學校法人順天堂 | 抗突變calr抗體與其他藥劑組合而成之醫藥 |
| US20250352627A1 (en) * | 2022-06-17 | 2025-11-20 | Ichan School Of Medicine At Mount Sinai | Mutant calr-peptide based vaccine |
| CN117003866B (zh) * | 2023-08-23 | 2025-06-06 | 复旦大学附属华山医院 | 一种抗calr突变蛋白抗体、制备方法及检测试剂盒 |
| WO2025207632A1 (en) * | 2024-03-26 | 2025-10-02 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for the treatment of myeloproliferative neoplasms |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20493A (en) * | 1858-06-08 | Bebtch-plaite | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US5846727A (en) * | 1996-06-06 | 1998-12-08 | Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College | Microsystem for rapid DNA sequencing |
| KR20010020238A (ko) | 1997-04-23 | 2001-03-15 | 버매스 존 디 | 칼레티쿨린 결핍 세포 |
| IL151904A0 (en) * | 2000-04-05 | 2003-04-10 | Genome Therapeutics Corp | THE HIGH BONE MASS GENE OF 11q13.3 |
| US7205146B1 (en) | 2000-06-14 | 2007-04-17 | Oscient Pharmaceuticals Corporation | Nucleotide and amino acid sequences relating to respiratory diseases and obesity |
| US6426220B1 (en) * | 2000-10-30 | 2002-07-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of calreticulin expression |
| US20020147165A1 (en) * | 2001-02-22 | 2002-10-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of calreticulin expression |
| GB0113266D0 (en) * | 2001-05-31 | 2001-07-25 | Bayer Ag | Genes and proteins for prevention prediction diagnosis prognosis and treatment of chronic lung disease |
| CA2595726A1 (en) | 2005-01-26 | 2006-08-03 | The Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
| JP4616237B2 (ja) | 2006-11-07 | 2011-01-19 | 日本電信電話株式会社 | シリコン化合物薄膜の形成方法 |
| CN101616029B (zh) † | 2009-07-28 | 2011-10-26 | 中兴通讯股份有限公司 | 一种实现网络拓扑发现的方法及系统 |
| WO2011069004A1 (en) * | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| US20140271683A1 (en) † | 2010-12-21 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor |
| CN103091499B (zh) * | 2013-01-23 | 2015-07-08 | 三峡大学 | 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用 |
| MX348980B (es) | 2013-09-16 | 2017-07-05 | Cemm-Forschungszentrum Für Molekulare Medizin Gmbh | Calreticulina mutante para la diagnosis de malignidades mieloides. |
-
2014
- 2014-09-15 MX MX2016003245A patent/MX348980B/es active IP Right Grant
- 2014-09-15 EP EP18215718.0A patent/EP3494985B1/en active Active
- 2014-09-15 PT PT141848358T patent/PT2808338E/pt unknown
- 2014-09-15 KR KR1020167008252A patent/KR102433548B1/ko active Active
- 2014-09-15 ES ES14184835.8T patent/ES2577289T3/es active Active
- 2014-09-15 PL PL18215718T patent/PL3494985T3/pl unknown
- 2014-09-15 CA CA2924370A patent/CA2924370C/en active Active
- 2014-09-15 RU RU2016114509A patent/RU2668808C2/ru active
- 2014-09-15 EP EP26162535.4A patent/EP4733417A2/en active Pending
- 2014-09-15 PL PL14184835.8T patent/PL2808338T3/pl unknown
- 2014-09-15 CN CN201480062698.8A patent/CN105916876A/zh active Pending
- 2014-09-15 SG SG11201601193TA patent/SG11201601193TA/en unknown
- 2014-09-15 US US14/486,973 patent/US9371570B2/en active Active
- 2014-09-15 DK DK14184835.8T patent/DK2808338T3/da active
- 2014-09-15 AU AU2014320262A patent/AU2014320262B2/en active Active
- 2014-09-15 US US15/021,906 patent/US10344335B2/en active Active
- 2014-09-15 JP JP2016542333A patent/JP6745220B2/ja active Active
- 2014-09-15 CN CN202610089526.4A patent/CN121951043A/zh active Pending
- 2014-09-15 CN CN202110912310.0A patent/CN113564254A/zh active Pending
- 2014-09-15 BR BR112016005611-6A patent/BR112016005611B1/pt active IP Right Grant
- 2014-09-15 DK DK18215718.0T patent/DK3494985T3/da active
- 2014-09-15 EP EP15196254.5A patent/EP3020727B2/en active Active
- 2014-09-15 EP EP14184835.8A patent/EP2808338B1/en active Active
- 2014-09-15 WO PCT/EP2014/069638 patent/WO2015036599A1/en not_active Ceased
- 2014-09-15 DK DK15196254.5T patent/DK3020727T4/da active
- 2014-09-15 EP EP17205289.6A patent/EP3339318B1/en active Active
-
2018
- 2018-02-22 US US15/902,859 patent/US20180251852A1/en not_active Abandoned
-
2019
- 2019-06-12 US US16/438,575 patent/US11274350B2/en active Active
- 2019-09-11 AU AU2019229353A patent/AU2019229353B2/en not_active Ceased
-
2022
- 2022-02-16 US US17/673,686 patent/US20220251666A1/en active Pending
- 2022-11-04 JP JP2022177306A patent/JP7646221B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537012A5 (https=) | ||
| JP6196338B2 (ja) | 診断および治療のための腫瘍関連抗原の同定 | |
| RU2016114509A (ru) | Мутантный кальретикулин для диагностики миелоидных новообразований | |
| AU2018229484B9 (en) | Treatment of fibrosis | |
| JP6285472B2 (ja) | 診断及び治療のための腫瘍関連マーカーの同定 | |
| JP2021534810A (ja) | Ｒｎａを編集する方法および組成物 | |
| JP2022518463A (ja) | 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞 | |
| JP6045563B2 (ja) | ドミナントネガティブｈｓｐ１１０突然変異体、並びにガンの予測及び処置におけるその使用 | |
| KR102138131B1 (ko) | 뇌 종양 동물 모델 및 이의 제조 방법 | |
| US20250277786A1 (en) | Gene activation targets for enhanced human t cell function | |
| CN109072312A (zh) | 癌症表观遗传谱分析 | |
| JP2017514514A (ja) | がんにおける融合遺伝子 | |
| CN102439174A (zh) | 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法 | |
| JP2024019511A (ja) | がんにおける融合遺伝子 | |
| JP7177439B2 (ja) | 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 | |
| JPWO2015033565A1 (ja) | 癌の診断、阻害剤のスクリーニングにおけるｒｈｏａの使用 | |
| JPWO2018030459A1 (ja) | 膵がんでのｃｌｄｎ１８−ａｒｈｇａｐ６融合遺伝子又はｃｌｄｎ１８−ａｒｈｇａｐ２６融合遺伝子の検出 | |
| AU2017285726A1 (en) | Methods for diagnosing and treating metastatic cancer | |
| JP2007534772A (ja) | ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物 | |
| WO2015129655A1 (ja) | Ｄｎａｊｂ１－ｐｒｋａｃａ遺伝子の検出方法 | |
| WO2017044946A1 (en) | Methods and compositions for modulating monocyte populations and related uses thereof | |
| US8309687B2 (en) | Biomarker specific for cancer | |
| JP2014054185A (ja) | 新規ｂｒａｆ融合体の検出法 | |
| WO2015023110A1 (ko) | 종양 질환 진단용 바이오마커 및 이의 용도 | |
| KR101748774B1 (ko) | 돼지 백혈구 항원(sla)-mic2 유전자의 다형성 분석방법 |